Abstract
Hydrophilic polymers are the most common group of polymers used in the preparation of modifiedrelease drug delivery systems. This is due to their versatility, low cost, high production yield, as well as easy manufacturing and adequate in vitro/in vivo correlation. In normal physiological conditions, the matrix controls the release of the loaded drug over time through a process of diffusion and/or erosion of the matrix, depending on its physicochemical composition. This is particularly relevant when describing the pharmacokinetic profile of nanosized drug delivery systems (nanoparticles). The use of mathematical models became an important tool to characterize the pharmacokinetics of drugs loaded in nanoparticles to improve the drug bioavailability and to establish bioequivalence. Therefore, the drug release profile can be predicted by a minimum number of experimental studies, since the mathematical equations reveal the dissolution rate of the drug loaded in the hydrophilic matrix. The present paper discusses the use of mathematical models when developing modified-release drug delivery systems of nanometer size composed of hydrophilic polymers.
Keywords: Hydrophilic polymers, mathematic modelling, modified release nanoparticles, pharmacokinetics.
Current Pharmaceutical Design
Title:Hydrophilic Polymers for Modified-Release Nanoparticles: A Review of Mathematical Modelling for Pharmacokinetic Analysis
Volume: 21 Issue: 22
Author(s): Tatiana Andreani, Joana F. Fangueiro, Sajan Jose, Antonello Santini, Amelia M. Silva and Eliana B. Souto
Affiliation:
Keywords: Hydrophilic polymers, mathematic modelling, modified release nanoparticles, pharmacokinetics.
Abstract: Hydrophilic polymers are the most common group of polymers used in the preparation of modifiedrelease drug delivery systems. This is due to their versatility, low cost, high production yield, as well as easy manufacturing and adequate in vitro/in vivo correlation. In normal physiological conditions, the matrix controls the release of the loaded drug over time through a process of diffusion and/or erosion of the matrix, depending on its physicochemical composition. This is particularly relevant when describing the pharmacokinetic profile of nanosized drug delivery systems (nanoparticles). The use of mathematical models became an important tool to characterize the pharmacokinetics of drugs loaded in nanoparticles to improve the drug bioavailability and to establish bioequivalence. Therefore, the drug release profile can be predicted by a minimum number of experimental studies, since the mathematical equations reveal the dissolution rate of the drug loaded in the hydrophilic matrix. The present paper discusses the use of mathematical models when developing modified-release drug delivery systems of nanometer size composed of hydrophilic polymers.
Export Options
About this article
Cite this article as:
Andreani Tatiana, Fangueiro F. Joana, Jose Sajan, Santini Antonello, Silva M. Amelia and Souto B. Eliana, Hydrophilic Polymers for Modified-Release Nanoparticles: A Review of Mathematical Modelling for Pharmacokinetic Analysis, Current Pharmaceutical Design 2015; 21(22) . https://dx.doi.org/10.2174/1381612821666150531163617
DOI https://dx.doi.org/10.2174/1381612821666150531163617 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Mitochondrial Neuroprotection in Traumatic Brain Injury: Rationale and Therapeutic Strategies
CNS & Neurological Disorders - Drug Targets Editorial: Relationship between Vitamin D and Metalloproteinases (MMPs) in Acute Myocardial Infarction (AMI)
Current Vascular Pharmacology Endothelial Dysfunction in Cardiac Allograft Vasculopathy: Potential Pharmacological Interventions
Current Vascular Pharmacology Neurotransmission Alterations in Central Cardiovascular Control in Experimental Hypertension
Current Hypertension Reviews C-arm CT Perfusion Imaging in the Interventional Suite
Current Medical Imaging The Interaction Between Gender and Diabetes Mellitus in the Coronary Heart Disease Risk
Current Pharmaceutical Design Medication-Induced Nephrotoxicity in Older Patients
Current Drug Metabolism Protein Aggregation and Self Assembly in Health and Disease
Current Proteomics Risk Scores and Prediction Models in Chronic Heart Failure: A Comprehensive Review
Current Pharmaceutical Design Type 2 Diabetes Mellitus and Invokana: An FDA Approved Drug
Current Diabetes Reviews Diagnostic Value of the Early Heart-to-Mediastinum Count Ratio in Cardiac 123I-mIBG Imaging for Parkinson's Disease
Current Radiopharmaceuticals Paracrine Mechanisms Involved in Mesenchymal Stem Cell Differentiation into Cardiomyocytes
Current Stem Cell Research & Therapy Skeletal Effects of Drugs to Treat Cancer
Current Drug Safety Heart Failure
Current Hypertension Reviews Cannabinoid 1 (CB1) Receptor - Pharmacology, Role in Pain and Recent Developments in Emerging CB1 Agonists
CNS & Neurological Disorders - Drug Targets Cerebral Microbleeds Do Not Predict Hemorrhagic Transformation in Acute Ischemic Stroke Patients with Atrial Fibrillation and/or Rheumatic Heart Disease
Current Neurovascular Research Pros and Cons of Medical Cannabis use by People with Chronic Brain Disorders
Current Neuropharmacology Possible Non-Classic Intracellular and Molecular Mechanisms of LDL Cholesterol Action Contributing to the Development and Progression of Atherosclerosis
Current Vascular Pharmacology Aptamers as Tools to Study Dysfunction in the Neuronal System
Current Medicinal Chemistry - Central Nervous System Agents Markers of Arrhythmogenic Risk in Hypertensive Subjects
Current Pharmaceutical Design